Statins for people at low risk of cardiovascular disease

The Lancet

Volumn 380, Issue 9856, 2012, Pages 1815-

  Battaggia, Alessandro ^a   Font, Maria ^a  

^a Dialogo sui Farmaci   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG EFFICACY; HEART DEATH; HUMAN; LETTER; LOW RISK POPULATION; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PUBLICATION; RANDOM ERROR; BLOOD; NOTE; VASCULAR DISEASE;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; VASCULAR DISEASES;

EID: 84869416480     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62022-4     Document Type: Letter

References (5)

1. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
2. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010; 170: 1024-31.
3. Therapeutics Initiative. Do statins have a role in primary prevention? An update. Therapeutics Letter 2010; 77: 1-5.
4. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
5. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA 2012; 307: 1302-09.